Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
Blood · 19.10.2023 · 142 (16) · 1371-1386
DOI: 10.1182/blood.2022018833 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Blood, erschienen am 19.10.2023. Verfasst von Vicky Brocklebank und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Ki…. Hauptthemen laut MEDLINE: Atypical Hemolytic Uremic Syndrome, Thrombotic Microangiopathies, Kidney Failure, Chronic. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of eculizumab with a short follow-up suggested efficacy. We prove, for the first time to our knowledge, in a genotype matched CaHUS cohort that the 5-year cumulative estimate of ESKD-free survival improved from 39.5% in a control cohort to 85.5% in the eculizumab-treated cohort (hazard ratio, 4.95; 95% confidence interval [CI], 2.75-8.90; P = .000; number needed to treat, 2.17 [95% CI, 1.81-2.73]). The outcome of eculizumab treatment is associated with the underlying genotype. Lower serum creatinine, lower platelet count, lower blood pressure, and younger age at presentation as well as shorter time between presentation and the first dose of eculizumab were associated with estimated glomerular filtration rate >60 ml/min at 6 months in multivariate analysis. The rate of meningococcal infection in the treated cohort was 550 times greater than the background rate in the general population. The relapse rate upon eculizumab withdrawal was 1 per 9.5 person years for patients with a pathogenic mutation and 1 per 10.8 person years for those with a variant of uncertain significance. No relapses were recorded in 67.3 person years off eculizumab in those with no rare genetic variants. Eculizumab was restarted in 6 individuals with functioning kidneys in whom it had been stopped, with no individual progressing to ESKD. We demonstrated that biallelic pathogenic mutations in RNA-processing genes, including EXOSC3, encoding an essential part of the RNA exosome, cause eculizumab nonresponsive aHUS. Recessive HSD11B2 mutations causing apparent mineralocorticoid excess may also present with thrombotic microangiopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom.
- Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
- Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
- Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom.
- Great North Children's Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle, United Kingdom.
- National Institute for Health and Care Research Newcastle Biomedical Research Centre, Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne, United Kingdom.
ORCID-Profile: Patrick R Walsh, Thomas M Hallam, Kevin J Marchbank, Theophile Bigirumurame, Tina Dutt, Emma K Montgomery, Michal Malina, Sally Johnson, Neil S Sheerin, David Kavanagh
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Brocklebank, V., Walsh, P. R., Smith-Jackson, K., Hallam, T. M., Marchbank, K. J., Wilson, V., Bigirumurame, T., Dutt, T., Montgomery, E. K., Malina, M., Wong, E. K. S., Johnson, S., Sheerin, N. S., & Kavanagh, D. (2023). Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood, 142(16), 1371-1386. https://doi.org/10.1182/blood.2022018833
Vancouver
Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, et al. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood. 2023;142(16):1371-1386. doi:10.1182/blood.2022018833
BibTeX
@article{Brocklebank2023,
author = {Brocklebank, Vicky and Walsh, Patrick R and Smith-Jackson, Kate and Hallam, Thomas M and Marchbank, Kevin J and Wilson, Valerie and Bigirumurame, Theophile and Dutt, Tina and Montgomery, Emma K and Malina, Michal and Wong, Edwin K S and Johnson, Sally and Sheerin, Neil S and Kavanagh, David},
title = {Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study},
journal = {Blood},
year = {2023},
volume = {142},
number = {16},
pages = {1371--1386},
doi = {10.1182/blood.2022018833}
}
EUVIMED